Consequently, eIF4A inhibitors hold therapeutic potential in combating cancer, viral infections as well as infections with different pathogens, like Plasmodium falciparum, Candida auris or Toxoplasma gondii [[17], [18], [19]]. Here, EIF4A1 is linked to infection.